# Eflornithine in Treating Patients With Bladder Cancer

> **NCT00003814** · PHASE3 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 450 (estimated)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** eflornithine

## Key facts

- **NCT ID:** NCT00003814
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-02
- **Primary completion:** —
- **Final completion:** 2007-05
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2013-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003814, "Eflornithine in Treating Patients With Bladder Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00003814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*